Trial Profile
An open label phase I study of fixed dose lapatinib in combination with an escalating dose of epirubicin in metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Epirubicin
- Indications Advanced breast cancer
- Focus Adverse reactions
- 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jan 2014 Planned End Date changed from 1 Sep 2009 to 1 Nov 2008 as reported by ClinicalTrials.gov record.